Brief: Mabion Signs Quality Agreement With Novavax
19/11/2021 16:53
Nov 19 (Reuters) - Mabion SA MABP.WA :
* SIGNS QUALITY AGREEMENT WITH NOVAVAX
* AGREEMENT COVERS TECHNICAL AND REGULATORY ARRANGEMENTS
REGARDING
PRODUCTION OF ANTIGEN OF VACCINE CANDIDATE FOR COVID-19 UNDER
NAME NUVAXOVID™
Source text for Eikon: ID:nEM1L9VPha
Further company coverage: MABP.WA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Mabion SA
See all newsBrief: Mabion Partner Oddifact Says FDA Consultations Allow MabionCD20 To Be Used As First-Line Therapy For ITP
Brief: Mabion Holds Pre-IND Type B Meeting With FDA On MabionCD20 Development For ITP
Brief: Mabion Signs LoI With WPD Pharmaceuticals On Extension Of Cooperation
Brief: Mabion Q2 Net Loss At 15 Mln Zlotys
Brief: Mabion Signs Deal With Novavax Expanding Cooperation To Analytical Services For Early-Stage Pipeline Projects